Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD117 + status confers therapeutic sensitivity to Imatinib in patients with Gastrointestinal Stromal Tumor.
The Republic of Ireland's Health Service Executive (HSE) has approved imatinib for reimbursement as a treatment option for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).